By 5W Public Relations
Publication Date: 2026-05-19 14:00:00
Five GLP-1 brands capture 57% of all AI citations in the $150 billion weight loss and metabolic health category; legacy programs and supplements losing visibility in real time
NEW YORK, May 19, 2026 /PRNewswire/ — Two pharmaceutical companies — Novo Nordisk and Eli Lilly — now own nearly 100% of GLP-1 citations inside the AI tools where Americans research weight loss, according to The Weight Loss & Metabolic Health AI Visibility Index 2026, released today by 5W, the premier AI communications and GEO firm in the United States.
The index ranks the top 25 U.S. brands in the weight loss and metabolic health category by their share of citations across ChatGPT, Claude, Perplexity and Google AI Overviews. It is the fourth installment in 5W’s AI Visibility Index series, following editions on Legal Tech, Real Estate and Fintech.
Five GLP-1 receptor agonists — Wegovy, Zepbound, Ozempic, Mounjaro and Saxenda — together capture roughly 57% of all category citations. The four leading brands alone capture 55%. Novo Nordisk and Eli Lilly are the only sources of FDA-approved options for chronic weight management and the only sources of the peer-reviewed clinical trial data — STEP, SURMOUNT and SELECT — that AI models cite as evidence.
The Top 15 by AI Citation Share:
- Wegovy — 19.0%
- Zepbound — 16.0%
- Ozempic — 13.0%
- Mounjaro — 7.0%
- Noom — 7.0%
- WeightWatchers — 7.0%
- MyFitnessPal — 6.0%
- Lose…
